JUSTIN KRAFFT: Open Payments
NPI 1245828904 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 41 payments from 11 companies in 2025. Trend: 2023 $758 · 2024 $1,430 · 2025 $1,022
Food & beverage: $1,022
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $300 |
| Travere Therapeutics, Inc. | 8 | $240 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $92 |
| Novartis Pharmaceuticals Corporation | 3 | $65 |
| Vifor Pharma, Inc. | 3 | $64 |
| Calliditas Therapeutics US Inc. | 2 | $59 |
| Amgen Inc. | 2 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| AKEBIA THERAPEUTICS INC | 1 | $20 |
Products named: FARXIGA, Filspari, JYNARQUE, Veltassa, TARPEYO, KRYSTEXXA, Vanrafia, TAVNEOS.
Industry payments across MO — which companies pay providers there.
